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Background. Ventilator-associated pneumonia (VAP) is the commonest hospital-acquired infection (HAI) in intensive care. In 
Asia, VAP is increasingly caused by resistant gram-negative organisms. Despite the global antimicrobial resistance crisis, the epide-
miology of VAP is poorly documented in Asia.
Methods. We systematically reviewed literature published on Ovid Medline, Embase Classic, and Embase from 1 January 1990 
to 17 August 2017 to estimate incidence, prevalence, and etiology of VAP. We performed a meta-analysis to give pooled rates and 
rates by country income level.
Results. Pooled incidence density of VAP was high in lower- and upper-middle-income countries and lower in high-income 
countries (18.5, 15.2, and 9.0 per 1000 ventilator-days, respectively). Acinetobacter baumannii (n = 3687 [26%]) and Pseudomonas 
aeruginosa (n = 3176 [22%]) were leading causes of VAP; Staphylococcus aureus caused 14% (n = 1999). Carbapenem resistance was 
common (57.1%).
Conclusions. VAP remains a common cause of HAI, especially in low- and middle-income countries, and antibiotic resistance 
is high.
Keywords. ventilator-associated pneumonia; review; Asia; antibiotic resistance.
Ventilator-associated pneumonia (VAP) is the single most com-
mon hospital-acquired infection (HAI) in intensive care units 
(ICUs) around the world [1, 2]. Patients who develop VAP have 
higher mortality, longer hospital stays, higher antibiotic usage, 
and more costly treatment than those without VAP [3–6].
Many low- and middle-income countries in Asia have rapidly 
developing economies with increasingly sophisticated provision 
of healthcare, resulting in more people accessing healthcare [7]. 
This, combined with a lack of regulation or enforcement on 
antibiotic dispensing, underdeveloped antibiotic stewardship, 
and infection prevention and control programs, has led to a cri-
sis in antibiotic resistance in hospital and community settings 
[8, 9]. In the hospital setting, ICUs often have the highest lev-
els of antibiotic resistance as a result of dealing with severely 
ill patients with high levels of HAI and antibiotic usage. VAP 
itself is associated with pathogens with high levels of antibiotic 
resistance, resulting in the need to treat with broad-spectrum 
antibiotics, which further drives antibiotic resistance [10–12].
In high-income countries, a combination of surveillance, 
education, and tailored intervention and prevention bundles 
have led to a reduction in the incidence of VAP [13]. In Asia 
there are limited data on rates of VAP, the common associated 
pathogens, and their antibiotic susceptibility profiles. This sys-
tematic review and meta-analysis of VAP incidence, prevalence, 
microbiological etiology, and cost summarizes these data by 
country income level and informs prevention and intervention 
guidelines and further research in the region.
METHODS
The systematic collection of data followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines. A literature search of 2 databases, Embase 
and Ovid, was performed from 1 January 1990 to 17 August 
2017. The search strategy was ventilator-associated pneumonia 
(meshed and unmeshed terms) AND Asia OR Afghanistan, 
Bahrain, Bangladesh, Bhutan, Brunei, Cambodia, China, Hong 
Kong SAR China, India, Indonesia, Iran, Iraq, Japan, Jordan, 
Kazakhstan, Kyrgyzstan, Kuwait, Laos, Lebanon, Macau SAR, 
Malaysia, Mongolia, Myanmar, Nepal, North Korea, Oman, 
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Pakistan, Qatar, Saudi Arabia, Singapore, South Korea, Sri 
Lanka, Syria, Taiwan, Tajikistan, Thailand, The Philippines, 
Turkmenistan, Uzbekistan, United Arab Emirates, Vietnam, 
Yemen. Articles were included for full screening if the abstract 
indicated there was prospective data on etiology, incidence den-
sity, period prevalence, or any details on the economic cost of 
VAP (see Figure  1 for details regarding inclusion of studies). 
Two independent reviewers assessed the titles and abstracts of 
papers for inclusion and any discrepancies were referred to a 
third independent reviewer. References of papers included were 
also assessed and included if they fit the inclusion criteria. Data 
were extracted onto a standardized form that was trialed on the 
first 3 papers and implemented after minor adjustments. Studies 
were categorized as those that gave period prevalence data (also 
referred to as cumulative incidence, defined as the number of 
episodes of VAP per 100 patients over a period of time, usu-
ally their ICU admission), incidence density data (number of 
episodes of VAP per 1000 ventilator-days, included if the total 
number of ventilator-days was also given), microbiology data 
with or without susceptibility, and any data on costing of VAP. 
Microbiology data were only included when the total number of 
organisms was given. Antibiotic resistance was classified using 
the European Centre for Disease Prevention and Control guide-
lines on surveillance of HAIs in the ICU [15]. Cost of VAP was 
collected in US dollars where possible and converted from local 
currency at the average rate for the year data was collected in the 
study. Study quality was assessed using the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) 
checklist for observational cohort and case-control studies, and 
the Consolidated Standards of Reporting Trials (CONSORT) 
checklist was used for randomized trials. Grading was deter-
mined by percentage completion of the checklist; high, ≥80% of 
items; moderate, 50%–80%; poor, <50% [16].
Countries were defined according to World Bank classifica-
tion of income level as low income (LIC), lower-middle income 
(LMIC), upper-middle income (UMIC), and high income 
(HIC) at the time the study was published [17]. There were only 
2 studies from LICs (both from Nepal) and therefore these were 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 flow diagram [14].
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included with LMICs for all group analysis. Countries were 
defined as tropical or nontropical based on their geographical 
latitude.
Data were analyzed using Stata software version 14 and 
Comprehensive Meta-analysis Software (www.meta-analysis.com). 
Data were pooled in all studies that reported the same outcome 
measures. The outcome measures of interest were incidence den-
sity as rate of VAP per 1000 ventilator-days with total number 
of ventilator-days as a denominator; period prevalence as rate 
of VAP per 100 patients over a given period of time; total num-
ber of microorganisms identified per country and proportion of 
individual species; and antibiotic resistance rates for a species as 
percentage of resistant organisms of that species by total number 
of organisms of that species identified per country. Meta-analysis 
was conducted on incidence density and period prevalence by 
weighted average estimates from individual studies. Forest plots 
were generated by Stata and meta-regression was used to analyze 
comparable groupings—country, income level, year published, 
study quality, study method (randomized controlled trials, obser-
vational cohort, pre-/postintervention, quasi-experimental), hos-
pital type (specialist, tertiary/university, district, multiple), and 
ICU type (general, medical, surgical, neurological, trauma, cor-
onary, multiple). Studies were assessed for heterogeneity using I2 
statistic and χ2 test (taking P < .05 to indicate statistically signif-
icant heterogeneity). When significant heterogeneity was found, 
then random-effects meta-analysis was used [18]. A  funnel 
plot was used to determine the probability of publication bias. 
Comparisons of rates were analyzed using mixed effect meta-re-
gression, an unrestricted maximum likelihood model.
Microbiological identification and susceptibility data were 
individually pooled by country and summary measures pre-
sented without use of meta-analysis.
RESULTS
A total of 88 studies covering 22 countries were included in the 
final data extraction. One hundred sixty-four were identified for 
full article review, and 76 were excluded for the following rea-
sons: non-English language (n = 10), pediatric (n = 5), lacking 
specific data (n = 21), retrospective (n = 7), non–journal article 
(n = 31), and unable to retrieve (n = 2) (Figure 1). The majority of 
studies were published in the last 10 years (2008 onward, 67/88 
[76%]). There were 69 (78%) studies of high quality, 19 (22%) of 
moderate quality, and none of poor quality. Data on VAP inci-
dence density were available from 31 articles and period preva-
lence from 74 articles. Microbiology data were available from 70 
studies, of which 49 also included data on resistance rates (see 
Supplementary Materials for full list of studies). The total num-
ber of patients in all studies was 564 355, and the total number 
of ventilator-days was 1 079 309 with 21 176 episodes of VAP. 
The median age of patients was 52.0 years (interquartile range, 
40.2–57.6 years) and sex was available for 141 354 patients, of 
whom 93 108 were male (65.9%).
Incidence Density and Prevalence Data
Data on incidence density were available from 14 countries, 
which included 538 600 patients, 1 076 140  days of mechan-
ical ventilation, and 16 082 episodes of VAP. The majority of 
these studies were published in the last 10 years (26/31 [84%]). 
Significant heterogeneity was observed in the studies as a whole 
(I2 = 100%) and when the studies were divided both by coun-
try and by income group (I2 approximately 99% in all catego-
ries). Therefore, all analysis was done using the random-effects 
model. The point estimate incidence density of VAP/1000 
ventilator-days in all studies was 15.1 (95% confidence inter-
val [CI], 12.1–18.0). Meta-analysis of incidence density per 
income level is presented in Table 1. There was a higher inci-
dence density rate in LMICs compared with HICs when ana-
lyzed by meta-regression (18.5 vs 9.0 per 1000 ventilator-days; 
P = .035). Meta-analysis of studies by study quality, study type, 
year of publication, hospital type, and ICU type did not show 
any significant difference in incidence density or prevalence 
(see Supplementary Materials for full analysis).
The pooled period prevalence of VAP for all studies 
was 12.7% (95% CI, 10.0–16.1). This includes 18 400 epi-
sodes of VAP and 549 478 patients. Meta-analysis of period 
prevalence per income level is presented in Table  1 (see 
Supplementary Materials for full analysis). Again, analysis 
Table 1. Incidence Density and Prevalence of Ventilator-associated Pneumonia From Meta-analysis Analyzed by Country Income Level
Pooled Incidence Density Rate (per 1000 VD) No. of Studies (95% CI) I2 P Value for Heterogeneity
LIC/LMIC 18.5 14 (15.6–21.4) 99.99 <.001
UMIC 15.2 9 (9.3–21.0) 99.99 <.001
HIC 9.0 8 (6.8–11.2) 99.99 <.001
Total 15.1 31 (12.1–18.0) 100.00 <.001
Pooled Period Prevalence Rate, %
LIC/LMIC 13.3 35 (8.6–20.2) 99.28 <.001
UMIC 15.4 24 (9.5–24.1) 99.67 <.001
HIC 8.0 15 (4.6–13.6) 99.10 <.001
Total 12.7 74 (10.0–16.1) 99.48 <.001
Abbreviations: CI, confidence interval; HIC, high-income country; LIC, low-income country; LMIC, lower-middle-income country; UMIC, upper-middle-income country; VD, ventilator-days.
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by study quality, study type, year of publication, hospital 
type, and ICU type did not show any significant difference. 
Period prevalence was highest in UMICs and lowest in HICs. 
Pooled incidence density and pooled prevalence data per 
country are presented in Table 2, and prevalence by country 
and region in Figure 2. The highest pooled incidence den-
sity was found in Mongolia (43.7/1000 ventilator-days) and 
the highest pooled prevalence in Hong Kong (48.1%), each 
based on 1 study [19, 20].
Microbiology
A total of 14 295 organisms were identified. The most common 
organism was Acinetobacter baumannii (n = 3687 [26%]), fol-
lowed by Pseudomonas aeruginosa (n = 3176 [22%]), Klebsiella 
pneumoniae (n  =  2008 [14%]), and Staphylococcus aureus 
(n = 1999 [14%]).
When the data were split by income level, A. baumannii was 
the most common organism in the LMIC group. However, 
the proportion due to this organism gradually reduced as 
income levels increased, and S. aureus and P. aeruginosa were 
the most common in the HIC group (Figure 3A). When the 
studies were divided by geographical latitude into tropical and 
nontropical regions, A. baumannii was more common in the 
tropical regions whereas S. aureus was a more common cause 
of infection in nontropical regions (Figure  3B). Aggregated 
microbiology data are presented by country for the top 7 
organisms in Figure 4.
Antimicrobial Resistance
Antimicrobial susceptibility of A.  baumannii was available 
from 34 studies, including a total of 1230 organisms tested. 
Carbapenem resistance was found in 702 isolates (57.1%). 
When grouped by income level, the resistance rate was 58% 
(199/342), 65% (457/706), and 26% (47/182) for LMICs, 
UMICs, and HICs, respectively. When divided into tropical and 
nontropical regions, the carbapenem resistance rate was 77.9% 
(307/394) and 47.3% (395/836), respectively.
Antimicrobial susceptibility of P.  aeruginosa was available 
from 35 studies, which included 1124 organisms. Carbapenem 
resistance was found in 414 isolates (36.9%). When grouped 
by income level, resistance was 41% (88/213), 42% (298/705), 
and 14% (28/206) in LMICs, UMICs, and HICs, respectively. 
Geographically, the carbapenem resistance rate among P. aeru-
ginosa in the tropics was 43% (167/388) compared with 34% 
(247/736) in the nontropical regions.
Resistance data on S. aureus were available from 38 studies, 
including 864 organisms. Overall, the proportion of S. aureus 
that was methicillin resistant (MRSA) was 67% (577/864), 
with 50% (26/50) in LMICs, 67% (331/493) in UMICs, and 
69% (220/319) in HICs. MRSA was equally common among 
S. aureus in the tropical and nontropical regions (64% [112/173] 
and 67% [466/691], respectively).
Antimicrobial susceptibility of K. pneumoniae to third-gen-
eration cephalosporins (625 organisms) and carbapenems (638 
organisms) were available from 30 studies. Cephalosporin 
Table 2. Pooled Results From Meta-analysis by Country, Incidence Density, and Period Prevalence
Country, by Income Level
Total No. of 
Studies Total No. of VD
Incidence Density 
per (1000 VD) (95% CI)
Total No. of 
Studies
Period  
Prevalence, % (95% CI)
LIC/LMIC
 Nepal 1 3364 21.4 (21.2–21.6) 2 21.7 (9.4–42.4)
 India 7 106 668 16.6 (12.5–20.7) 23 14.3 (7.5–25.8)
 Mongolia 1 618 43.7 (43.2–44.2) 1 5.8 (4.0–8.3)
 Pakistan … … … … 1 15.5 (12.7–18.6)
 Philippines 1 10 041 16.7 (16.6–16.8) 1 4.3 (3.6–5.1)
 Sri Lanka … … … … 1 26.5 (17.4–38.2)
 Jordan … … … … 1 8.1 (7.0–9.2)
UMIC
 China 6 628 193 19.0 (12.1–25.9) 9 11.4 (5.1–23.5)
 Iran 1 6976 7.9 (7.8–7.9) 10 18.2 (9.3–32.5)
 Lebanon 1 3561 8.1 (8.0–8.2) 2 16.7 (1.1–78.8)
 Malaysia … … … … 2 12.6 (2.3–47.6)
 Thailand 5 43 692 8.8 (6.6–11.0) 6 13.2 (5.6–28.2)
HIC
 Hong Kong … … … … 1 48.1 (30.4–66.4)
 Japan 1 51 361 12.6 (12.6–12.6) 1 2.9 (2.7–3.2)
 Kuwait 2 17 465 8.8 (8.1–9.4) 2 2.5 (1.0–6.0)
 Saudi Arabia 2 32 988 3.6 (1.7–5.4) 4 11.1 (5.2–22.2)
 Singapore … … … … 1 8.1 (4.5–14.0)
 Taiwan 2 94 464 10.1 (5.0–15.2) 6 7.9 (2.3–23.9)
 3 Gulf countriesa 1 76 749 4.8 (4.8–4.8) … … …
Abbreviations: CI, confidence interval; HIC, high-income country; LIC, low-income country; LMIC, lower-middle-income country; UMIC, upper-middle-income country; VD, ventilator-days.
aBahrain, Oman, Saudi Arabia.
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resistance was found in 370/625 (59%) isolates and carbapenem 
resistance in 101/638 (15.8%) isolates.
Antimicrobial susceptibility of Escherichia coli to third-gen-
eration cephalosporins (165 organisms) and carbapenem (152 
organisms) were available from 22 and 19 studies, respectively. 
Cephalosporin resistance was found in 127/165 (77%) isolates 
and carbapenem resistance in 41/152 (27%) isolates.
Cost Burden of VAP
There were very few data available on the costs of VAP in Asia. 
Only 5 studies in our review included any information on the 
economic burden of VAP and these used different methodolo-
gies and therefore could not be compared. Three studies gave 
ICU costs of patients with and without VAP. In 2011–2012, in 
Ludhiana, India, it was estimated that the average cost of an 
ICU admission for a patient with VAP was $6250.92 compared 
with $2598.84 for a patient without VAP [21]. In Tehran, Iran, 
in 2012–2013, VAP cost 3.04 purchasing power parity (PPP) per 
day, compared with 1.23 PPP per day for those without VAP 
[22]. In Taipei, Taiwan in 2011–2014, an average ICU admis-
sion with VAP cost $8924.50 compared with $6625.50 without 
[23]. One further study in 2011–2012 in Goa, India, calculated 
the average additional cost of antibiotics used to treat VAP at 
$432.7 [24]. An additional study estimated the cost benefit of 
introducing a VAP educational bundle in Thailand and found 
the average hospital cost per patient admitted to ICU was $4769 
prior to the bundle and $2378 after the bundle [25].
DISCUSSION
VAP remains a major contributor to HAIs in Asia. This sys-
tematic review highlights very worrying aspects of the ongo-
ing crisis in HAIs and antibiotic resistance affecting this region. 
The incidence density of VAP remains high in both LMICs and 
UMICs, demonstrated by no indication of a reduction over time 
on meta-analysis. Given the large expansion of ICUs in these 
settings, the at-risk population can be expected to rise sub-
stantially in the immediate future, compounding the problem. 
Additionally, for LMICs anticipating a resolution of the problem 
as their economies grow, the data from the UMICs in the region 
are worrying. There are major omissions in the published data 
from many of the countries included in this review with only 
Figure 2. Mapped period prevalence rates of ventilator-associated pneumonia for 74 studies in Asia. The prevalence rates reported are color coded. Source: http://
naturalearthdata.com.
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22 of 40 countries having any published data at all. The chang-
ing trend in microbiological etiology from previous published 
reviews (where S. aureus was the predominant microorganism) 
and the rate of resistance in these organisms reinforces the pic-
ture of a global antibiotic crisis [26, 27].
Incidence Density and Prevalence Data
To our knowledge, this is the first review to analyze incidence 
data by national income level. We have demonstrated a trend 
in the incidence density of VAP by income level but no trend 
in the period prevalence. Our pooled period prevalence has 
demonstrated that UMICs also have a significant burden of 
VAP and that this may be higher than LMICs. When com-
paring with other international VAP studies, the International 
Nosocomial Infection Control Consortium (INICC) report 
from 2009 gives a pooled density of 13.6 per 1000 venti-
lator-days, which includes data from Latin America, Asia, 
Africa, and Europe [28]. Our overall rate is similar to this; 
however, when taking the LMIC alone, we have shown much 
higher rates, similar to those documented in a systematic 
review of developing countries globally (22.9/1000 ventila-
tor-days) [29].
It is currently complicated to compare national rates of VAP 
with the rate in the United States due to changing definitions 
and means of classifying VAP [30]. However, the published 
rates of 0.0–5.8 per 1000 ventilator-days in the United States 
are comparable to some but not all of the studies from HICs 
in this review [31]. Previous reviews have quoted incidence 
density rates of 2–16 per 1000 ventilator-days (from the INICC 
and United States), whereas we have found much higher rates 
in some of our studies (0.50–76.83) [32]. A systematic review 
and meta-analysis of VAP in China determined the incidence 
density at 24.14 episodes per 1000 ventilator-days [33]. This is 
higher than the rate we have found in China (19.0/1000 venti-
lator-days). Whereas we included 13 articles from China, the 
aforementioned review included 195 additional studies pub-
lished in non–English-language journals, suggesting higher 
rates in these publications.
Microbiology and Resistance Rates
This review adds to the evidence of A. baumannii as the primary 
organism associated with VAP; it is the commonest organism in 
LMICs and in countries in the tropics and has high rates of anti-
microbial resistance in these regions. This is the first systematic 
Figure 3. A, Pooled microbiology results of ventilator-associated pneumonia (VAP) etiology by country income level. B, Pooled microbiology results of VAP etiology by 
geographic area (tropical vs nontropical). Abbreviations: HIC, high-income country; LMIC, low-/lower-middle-income country; UMIC, upper-middle-income country.
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review to collate studies from Asia that demonstrates A. bauman-
nii as the main cause of VAP [11, 34]. Other studies have demon-
strated other gram-negative bacteria, such as P.  aeruginosa, as 
a major cause of VAP [10]. However definitive conclusions are 
hard to draw since the diagnosis of VAP is complicated and iso-
lated pathogens may be colonizers and not the causative agent.
The resistance rates we have found are similar to those docu-
mented by the INICC and others globally and demonstrate a 
worrying rise in resistance in all pathogens to even the broadest 
antibiotics (eg, rates of carbapenem resistance in A. baumannii at 
approximately 75%) [35–38]. Resistance rates to colistin were not 
available in any of the studies. Our review confirms what multi-
ple single-site studies and expert reviews have stated, that resistant 
gram-negative bacteria are the major cause of VAP in Asia [37, 39].
Cost Burden of VAP
There is very sparse information on the health economic impact 
of VAP in Asia. There are several studies describing the disease 
burden of HAI in Asia or LMIC settings, all of which have 
found high rates of VAP and a significant increase in mortality 
and length of stay [16, 29, 40]. Our study aimed to summarize 
this sparse literature on direct economic burden of VAP, but due 
to the lack of published data on this we are unable to draw any 
definitive conclusions. It would appear that VAP is a significant 
cause of patient morbidity and mortality, that the rates remain 
high, and that cost of prevention bundles in this setting are both 
clinically and financially worthwhile.
Our study is limited by the inclusion of only English-language 
journals. We excluded several studies from our search due to use 
of a non-English language and we did not search non-English-lan-
guage databases. In addition, there was a large degree of hetero-
geneity in our studies, which we have attempted to compensate 
for by using the random-effects model for meta-analysis, but the 
underlying differences in the studies remain. These differences 
result from the wide geographical area covered as well as different 
practices within the ICU, different patient groups within the ICUs, 
and different definitions used to diagnose VAP. Due to the publi-
cation bias and heterogeneity, any conclusions and extrapolations 
to other populations should be undertaken with caution.
In conclusion, VAP is a significant burden in Asia, with 
LMICs and UMICs both demonstrating higher rates than 
HICs. There is a worrying amount of antibiotic resistance in 
Figure 4. Mapped pooled microbiology results by country for etiology of ventilator-associated pneumonia. Organisms are color coded, and the size of the pie chart reflects 
the total number of isolates identified per country. Source: http://naturalearthdata.com.
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the pathogens causing VAP and unless concerted international 
effort is made, this is likely to worsen.
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